Expression of Kruppel-like factor 8 and Ki67 in lung adenocarcinoma and prognosis

Abstract

Kruppel-like factor 8 (KLF8) belongs to the KLF family and has various roles in the regulation of the cell cycle, proliferation and tumor genesis. KLF8 is overexpressed in gastric, ovarian, breast and renal cancer. Additionally, KLF8 may affect invasion and metastasis of tumors. However, whether KLF8 also acts as an ontogeny in lung adenocarcinoma (LAC) remains unknown. The aim of the present study was to determine the association between KLF8 expression and various clinical and pathological parameters. Western blot assays and immune histochemistry analyses revealed that KLF8 level in LAC tissues was higher than that in the normal lung tissues and KLF8 expression was significantly associated with clinical variables (P<0.05). Kaplan-Meier curves revealed that high expression of KLF8 was related to poor prognosis in patients with LAC. The present study also demonstrated that KLF8 was involved in the progression of lung adenocarcinoma. This data suggested that KLF8 may act as a prognostic factor in lung adenocarcinoma progression.

Introduction

Lung cancer is a threat to people's health and life, and according to the pathological features it may be divided into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC accounts for ~80% of all lung cancer cases (1). Adenocarcinoma is the most common pathological type of NSCLC (1). Although surgery, comprehensive treatment and postoperative chemotherapy have been applied to treat lung cancer, the 5-year survival rate of lung cancer is only 10–15% (2,3).

Kruppel-like factor 8 (KLF8) is a member of the KLF family and has various roles in the regulation of the cell cycle, apoptosis, proliferation, differentiation, development and carcinogenesis (4–6). Previous studies have demonstrated that KLF8 is identified in various types of cancer to a large extent, including gastric, lung, ovarian, breast and renal cancer (7–9). KLF8 may also affect the invasion and metastasis of tumors (10). However, no data is currently available on KLF8 in lung adenocarcinoma (LAC).

Ki67 is a nuclear protein that is associated with cellular proliferation (11). Ki67 protein is present during all active phases of the cell cycle (G1, S, G2 and mitosis) (11). Ki67 has a short life span, thus it is absent in resting cell phases (G0) (12). Ki67 has been widely used as a cell proliferation marker to determine the degree of growth, invasion and prognosis of cancer (13).

The present study aimed to investigate the expression of KLF8 in LAC, the association between KLF8 and clinical features, and the expression of Ki67 in patients with LAC. The relationship between KLF8 and patient survival was also investigated in Kaplan-Meier survival curves.

Materials and methods

LAC tissues were collected from 140 patients who underwent surgical resection without preoperative systemic chemotherapy or radiotherapy at the Affiliated Hospital of Nantong University (Nantong, China) between January 2009 and December 2010. LAC tissues were obtained by surgery using protocols approved by the Ethics Committee of the Affiliated Hospital of Nantong University. Written informed consent was provided by all patients enrolled in the study. Among the cases, there were 72 male and 68 female patients. These patients were aged between 39–77 years, and the mean age was 61 years. All samples were fixed in 10% buffered formalin for 24 h, which was performed at 20°C and embedded in paraffin at the time of collection. All 140 patients with LAC had corresponding history data and follow-up records.

Tumor tissues of these 140 specimens and corresponding tumor-adjacent tissues were used for construction of tissue microarrays (TMA). Briefly, each patient's tumor was represented by 2.0-mm cores. Hematoxylin and eosin-stained slides (4-µm thick) for each patient were histologically analysed using an Olympus BX41 microscope (magnification, ×200; Olympus Corporation, Tokyo, Japan) according to the the Union for International Cancer Control (UICC) TNM staging system predominantly for the scope of the primary tumor, regional lymph node metastasis and distant metastasis stage.

Another 8 samples of tumor tissues and adjacent non-tumor tissue were collected for western blot analysis. These samples were collected from 8 cases of patients who underwent curative resection between January 2009 and December 2010 of LAC tissues in the same hospital. Fresh samples were frozen in liquid nitrogen immediately after surgical removal and maintained at −80°C until they were used for western blot analysis.

Western blot analysis

Protein was extracted from ~0.1 g of fresh tissue from the 8 cases of tumor and matched adjacent normal samples. Tissues were immediately homogenized in a homogenization buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% NP-40, 5 mM EDTA, 60 mM β-glycerophosphate, 0.1 mM sodium orthovanadate, 0.1 mM NaF and complete protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland), and then centrifuged at 12,000 × g for 30 min to collect the supernatant (4°C). The bicinchoninic acid assay method was used to determine the protein concentration in the samples after the addition of SDS buffer and 100°C for 10 min. Following this, protein samples (60 µg) were separated with 12% SDS-PAGE and transferred to polyvinylidene fluoride membranes. The membranes were blocked with Tris-buffered saline with Tween-20 (TBST) supplemented with 5% skimmed milk for 1 h and then incubated with rabbit anti-human KLF8 antibody (1:150; ARP31533 P050; Aviva Systems Biology Corp., San Diego, CA, USA) or mouse anti-human GAPDH antibody (1:150; OAAD00231; Aviva Systems Biology Corp) overnight at 4°C. Membranes were washed three times with TBST and incubated with goat anti-rabbit IgG-HRP (1:8,000; sc-2004) and goat anti-mouse IgG-HRP (1:5,000; sc-2005; both from Santa Cruz Biotechnology, Inc., Santa Cruz, USA) secondary antibodies for 2 h at room temperature. Enhanced chemiluminescence reagents (Thermo Fisher Scientific, Inc.) were used for band detection using a Tanon 5200 Imaging System (Tanon Science Technology Co., Shanghai, China). The band intensity was measured using the ImageJ 1.40 analysis system (National Institutes of Health, Bethesda, MD, USA).

Immunohistochemistry

The EnVision method (14) was used for immunohistochemical staining. A total of 140 LAC samples were produced for TMA. The samples were incubated for 40 min at 70°C, dewaxed and dehydrated in graded ethanol. Using TMA in antigen repairing 22 min at 99°C, dripping with 3% hydrogen peroxide for 20 min at room temperature. Then the samples were washed with phosphate-buffered saline with Triton X-100 three times, and incubated with rabbit anti-human KLF8 antibody (1:150; Aviva Systems Biology Corp.) or rabbit anti-human Ki67 (1:500; ab15580; Abcam, Cambridge, UK) overnight at 4°C. Subsequently, the samples were incubated with goat anti-rabbit IgG-HRP antibody (1:500; sc-2004; Santa Cruz Biotechnology, Inc.) for 2 h at room temperature. PBS was used as a negative control instead of the primary antibody. The Olympus BX41microscope was used to capture images of the samples.

Evaluation of staining

The analysis of these sections following immunostaining was conducted by two independent experienced pathologists. Both pathologists were unaware of the clinical pathological data and patient's outcome. KLF8 was predominantly located in the cytomembrane, also it was also observed in the cytoplasm and nuclei. Ki67 was also located in tumor cell nuclei. The positive cells were those with yellow/brown granules in the nucleus and whose staining intensity was higher than those with specific staining in the background. Under the microscope (magnification, ×400), 100 cells were counted at each site, and the staining intensity and the percentage of positive cells were recorded in four sites. The staining intensity score assessment was as follows: 0, no staining; 1, weakly stained; 2, moderately stained; and 3, strongly stained. The final score was the product of KLF8 and Ki67 staining: <3 points was defined as negative and low staining; and ≥3 points was defined as positive and high staining.

Statistical analysis

Statistical analysis was performed using SPSS v. 21.0 (IBM Corp., Armonk, NY, USA). The relationship between KLF8, Ki67 and clinical pathological features of lung adenocarcinoma were examined using χ² testing. The correlation between KLF8 and Ki67 was analyzed according to Spearman's rank correlation. Survival curves were calculated by the Kaplan-Meier method. P<0.05 was considered to indicate a statistically significant difference.

Results

KLF8 is present in LAC samples at high levels

In an attempt to verify whether KLF8 was involved in LAC, protein expression levels of KLF8 in 8 tumor tissue samples and adjacent non-tumor tissue were analyzed by western blot analysis. It was demonstrated that KLF8 expression levels were markedly higher in tumor samples than in normal lung samples (Fig. 1). Immunohistochemical staining was conducted on 140 LAC samples. As demonstrated in Fig. 2, positive cell percentages of KLF8 were as follows: <10% (Fig. 2E); F, 11–50% (Fig. 2F); G, 51–75% (Fig. 2G); and >75% (Fig. 2H).

Figure 1.

Expression of KLF8 was detected in 8 paired cases of lung adenocarcinoma and adjacent non-tumor tissue. GAPDH was used as a loading control. T, tumor tissue; N, non-tumor tissue; KLF8, Kruppel-like factor 8.

Figure 2.

Expression of (A-D) Ki67 and (E-H) KLF8 in lung adenocarcinoma and adjacent non-tumor tissue by immunohistochemistry. (A and E) Adjacent non-tumor tissue. (B and F) Well-differentiated LAC. (C and G) Moderately differentiated LAC. (D and H) Poorly differentiated LAC. Magnification, ×200; Scale bar, 50 µm. KLF8, Kruppel-like factor 8, LAC, lung adenocarcinoma.

Correlation exists between KLF8 expression and clinical pathological parameters in patients with LAC

The relationship between KLF8 protein expression levels and patient clinical pathological parameters (Table I) was analyzed. KLF8 expression was significantly correlated with differentiation (P=0.035), TNM (P=0.001), lymph node metastasis (P=0.015) and median survival (P=0.018). However, no significant association was identified between KLF8 expression and the other clinical pathological characteristics, including sex, age and tumor size. Furthermore, there was a significant positive association between KLF8 and Ki67 expression (Table II; P<0.01). Additionally, the correlation between KLF8 and Ki67 was analyzed by using Pearson's rank correlation, which indicated a significant positive correlation between the expression of these proteins (r=0.511; P<0.05; Fig. 3).

Table I.

KFL8 and Ki67 expression and clinicopathological parameters in 140 lung adenocarcinoma samples.

		KLF8 expression
Parameters	Total	Low	High	% of total	x2	P-value
Sex						0.057
Male	72	34	38	52.8	3.623
Female	68	43	25	36.8
Age, years						0.731
<60	60	34	26	43.3	0.118
≥60	80	43	37	46.3
Tumor size, cm						0.170
<3	60	37	23	38.3	1.886
≥3	80	40	40	50.0
Differentiation						0.035
Well	33	23	10	30.3	6.707
Moderate	71	40	31	43.7
Poor	36	14	22	61.1
TNM stage						0.001
I	69	48	21	30.4	16.915
II	34	17	17	50.0
III	31	12	19	61.3
IV	6	0	6	100
Lymph node metastasis						0.015
No	78	50	28	35.9	5.896
Yes	62	27	35	56.5
Median survival, months						0.018
<37	69	31	38	55.1	5.577
≥37	71	46	25	35.2
Ki67 expression						<0.01
High	101	43	58	57.4	22.618
Low	39	34	5	12.8

KLF8, Kruppel.like factor 8.

Table II.

Correlation between expression of KLF8 and Ki67 in 140 lung adenocarcinoma specimens.

	KLF8 expression
Ki67 expression	High	Low	r	P-value
High	58	43	0.402	<0.01
Low	5	34

KLF8, Kruppel-like factor 8.

Figure 3.

Correlation between KLF8 and Ki67 expression in lung adenocarcinoma was further evaluated by Pearson's rank correlation. KLF8, Kruppel-like factor 8.

KLF8 and Ki67 expression correlates with patient survival

The association between KLF8 expression and patient survival status was investigated. Kaplan-Meier survival curves demonstrated that high expression of KLF8 was significantly correlated with poor overall patient survival (Fig. 4A; P=0.011). The prognosis of patients with high expression of KLF8 was worse than the prognosis of patients with lower expression levels. Furthermore, patients with higher expression levels of Ki67 demonstrated a significantly reduced survival rate compared with those who had low expression levels of Ki67 (P<0.01; Fig. 4B).

Figure 4.

Overall survival curve of patients with lung adenocarcinoma according to high or low expression of (A) KLF8 and (B) Ki67. KLF8, Kruppel-like factor 8.

Discussion

Lung cancer is one of the most common malignant tumors in China (15). The main causes of lung cancer include smoking, environmental pollution, population aging and lifestyle changes (15). A variety of molecular pathways and proteins participate in the development of LAC, and the current medical level is incapable of diagnosing LAC at an early stage, meaning that it usually metastasizes before being clinically diagnosed (3). Therefore, it is vital to identify new specific molecules to predict LAC prognosis.

KLFs are recognized as transcriptional inhibitor proteins of the Kruppel-like cys2/His2 zinc finger protein family (16). KLFs are DNA-binding transcription regulation factors, with a highly conserved zinc finger structure in the C-terminal domain, which may combine with a variety of gene promoter components, particularly the GC box (17). The KLF family has an important role in cell cycle regulation and cell proliferation and also has an important function in the process of tumor development, invasion and metastasis (4,18). The KLF family is composed of 14 members, KLF1-14. KLF8 was isolated from K562 leukemia and has been the focus of research (19). KLF8 is located on the X chromosome in humans and consists of 359 amino acid residues (20). The zinc fingers of KLF8 identify CACCC elements in DNA, and the full-length KLF8 may inhibit a CACCC-dependent promoter (21). Sometimes the zinc finger domain regulates protein-protein interactions (4,16). Some researchers believe that KLF8 may be stimulated by small ubiquitin like modifiers (SUMO)-1, SUMO-2 and SUMO-3, primarily by SUMO-1 (17). Research has demonstrated that the function of KLF8 is limited when SUMO-1 is bound at Lys67 (17,22,23).

Various studies have demonstrated that high expression of KLF8 exists in a variety of tumors, including as breast (24,25), ovarian (26), bladder (27) and gastric cancer (28,29). A previous study indicated that KLF8 may act on matrix metalloproteinase 9 transcription in breast cancer, promoting cell invasion and metastasis of human breast cancer (24). KLF8 is also tightly regulated by focal adhesion kinase through Src and phosphoinositide 3-kinase signaling pathways via transcription factors specificity protein 1, KLF1 and KLF3 (26,30). KLF8 also regulates the expression of vimentin and N-cadherin, and increases the expression of β-catenin, thus promoting the proliferation and migration of bladder cancer cells (27). In addition, KLF8 regulates epithelial-mesenchymal transition (EMT) induced by transforming growth factor (TGF)-β1 in gastric cancer cells (28). Downregulation of KLF8 by small interfering RNA has been demonstrated to block TGF-β1-induced EMT-like transformation and TGF-β1-prompted cell migration, invasion and motility (28).

In the present study, the expression of KLF8 in 8 paired cases of fresh lung adenocarcinoma tissues and non-cancerous tissues was investigated using western blotting. The results demonstrated that the expression of KLF8 in lung adenocarcinoma was markedly higher than that in non-cancerous tissues. Additionally, the expression of KLF8 and Ki67 in patients with LAC using TMA was evaluated. High expression of KLF8 was significantly correlated with differentiation, TNM and lymph node metastasis. Furthermore, the expression of KLF8 was correlated positively with Ki67. The patients with high expression levels of KLF8 or Ki67 had a worse prognosis than those with low expression levels of KLF8. In conclusion, the KLF8 protein may be a novel therapeutic target for LAC; however, further study of the molecular mechanisms of KLF8 in LAC is required.